menu
    • menu
    [{"orgOrder":0,"company":"Royal DSM","sponsor":"Humanetics Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Genistein","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Royal DSM \/ Humanetics Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Royal DSM \/ Humanetics Corporation"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Adare Biome","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Lactobacillus LB","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Royal DSM","amount2":0.29999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0.29999999999999999,"dosageForm":"Capsule","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"12","companyTruncated":"Royal DSM \/ Royal DSM"}]

    Find Clinical Drug Pipeline Developments & Deals by Royal DSM

    Menu

    Royal DSM

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Royal DSM

                            Netherlands arrow
                            PharmaVenue
                            Not Confirmed

                            Royal DSM

                            Netherlands arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus LB

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Recipient : Adare Biome

                            Deal Size : $302.8 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            DSM Agrees Terms To Acquire Postbiotics Pioneer Adare Biome

                            Details : The acquisition will facilitate DSM to anticipate in the rapidly extension of the availability of Lacteol (lactobacillus LB), an effective postbiotic treatment for diarrhea, engineered using adare's innovative microbiome technology platform, for people t...

                            Brand Name : Lacteol

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 19, 2023

                            Lead Product(s) : Lactobacillus LB

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Recipient : Adare Biome

                            Deal Size : $302.8 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Royal DSM

                            Netherlands arrow
                            PharmaVenue
                            Not Confirmed

                            Royal DSM

                            Netherlands arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Genistein

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Humanetics Corporation

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Humanetics Acquires Manufacturing Assets for Radioprotectant

                            Details : Included in the acquisition are patents, trademarks, trade secret manufacturing processes, analytical methods, regulatory filings, and a large number of nonclinical and clinical safety studies.

                            Brand Name : BIO 300

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 19, 2020

                            Lead Product(s) : Genistein

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Humanetics Corporation

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth